Allspring Global Investments
STLN

Allspring Global Investments’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

Allspring Global Investments’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-35,744
Closed -$24.2K – 2835
2023
Q1 		$24.2K Buy
35,744
+25,059
+235% +$32K ﹤0.01% 2467
2022
Q4 		$17.6K Sell
10,685
-234
-2% -$657 ﹤0.01% 2616
2022
Q3 		$50K Buy
+10,919
New +$64.2K ﹤0.01% 2358

Other funds holding STLN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return
TM
Triatomic Management Palo Alto, California $3.39M AUM 3.35% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Allspring Global Investments's STLN Position: Q2 2023 in Review

Allspring Global Investments sold out of Starling Oncology Institute, Inc. Common Stock (STLN) in Q2 2023, closing a stake of 35,744 shares — an estimated $24.2K sold.

Allspring Global Investments first reported a position in STLN in Q3 2022 and held it in 3 quarters. The position peaked at $50K in Q3 2022. 38 funds tracked by Wall St. Rank hold STLN as of Q2 2023.

  • Allspring Global Investments reported no remaining Starling Oncology Institute, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Allspring Global Investments sold 35,744 Starling Oncology Institute, Inc. Common Stock shares in Q2 2023, an estimated $24.2K.
  • Allspring Global Investments first reported a position in Starling Oncology Institute, Inc. Common Stock in Q3 2022 and held it in 3 quarters.
  • Allspring Global Investments's Starling Oncology Institute, Inc. Common Stock position peaked at $50K in Q3 2022.
  • 38 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q2 2023.

Based on Allspring Global Investments's 13F filing for Q2 2023, filed 18 Jul 2023.